News Focus
News Focus
Followers 38
Posts 1153
Boards Moderated 0
Alias Born 03/20/2013

Re: biosectinvestor post# 421854

Saturday, 11/27/2021 8:26:45 AM

Saturday, November 27, 2021 8:26:45 AM

Post# of 817892
I always appreciate you post Bio, I'm going to stay in the camp of pseudo progression, I heard the same story in regards to pseudo progression from the Ipilimumab team when they were running the phase 3 trial for melanoma. So what's your opinion on what caused the halt? Take a look at these melanoma trials, Yervoy is a multibillion dollar drug and the response rate really isn't that great. Just think of what DCVax can do?
"Moreover, in the pivotal phase 3 trial conducted in previously treated patients with advanced melanoma, the best overall response rate was only 11% for ipilimumab. 25 This was consistent with best overall response rates of 4% to 16% in phase 2 studies of ipilimumab monotherapy (Table 6).36–39"

https://pubmed.ncbi.nlm.nih.gov/20525992/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3462607/
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News